A Prospective, Single-Arm, Exploratory Study of the Safety and Efficacy of Neoadjuvant Treatment With QL1706, an Anti-PD-1/Anti-CTLA-4 Bispecific Antibody, in Resectable Stage IB and IIA Hepatocellular Carcinoma With High Recurrence Risk

NCT07515469 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

HCC - Hepatocellular Carcinoma
Iparomlimab and Tuvonralimab Injection
Neoadjuvant Immunotherapy

Interventions

DRUG: Iparomlimab and Tuvonralimab

Sponsor

Tianjin Medical University Cancer Institute and Hospital